Oncology & Cancer

Dose analysis predicts non-Hodgkin lymphoma survival

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art ...

Medical research

DNA-altering enzyme is essential for blood cell development

The expression of specific genes is partially dictated by the way the DNA is packed into chromatin, a tightly packed combination of DNA and proteins known as histones. HDAC3 is a chromatin-modifying enzyme that regulates ...

Oncology & Cancer

TCE exposure linked to increased risk of some cancers

Trichloroethylene (TCE) exposure has possible links to increased liver cancer risk, and the relationship between TCE exposure and risks of cancers of low incidence and those with confounding by lifestyle and other factors ...

Oncology & Cancer

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

Oncology & Cancer

Cancer survivors battle with the blues

Depressed cancer survivors are twice as likely to die prematurely than those who do not suffer from depression, irrespective of the cancer site. That's according to a new study, by Floortje Mols and colleagues, from Tilburg ...

Medications

Simponi approved for ulcerative colitis

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Oncology & Cancer

Searching for therapeutic synergy in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...

page 39 from 40